Clinical trials: Neuronal Ceroid Lipofuxinosis Type2 (CLN2)
Neuronal Ceroid Lipofuxinosis Type2 (CLN2)
A Multicenter Selective Screening Study to Investigate the Frequency of Neuronal Ceroid Lipofuxinosis Type 2 (CLN2)
This study is a multicenter, non-drug screening study. Enrollment period is 12 months. There are no IMP to be followed or used in the study.
- Trial name
- ENIGMA (NCT06128226)
- Testing
- Blood Sampling
- Where
- 34 sites in Turkey (Türkiye)
- Volunteers
- 750 people
- Sponsor
- Nadir Hastalıkları Araştırma Derneği